메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Hope Medicine Inc. Announces Successful Completion of a Global Phase 2 Study of a Potential First-in-Class Endometriosis Treatment

[ 메디채널 김갑성 기자 ] HMI-115 demonstrated statistically significant improvement in endometriosis pain The mean dysmenorrhea pain score was reduced by 42% The mean non-menstrual pelvic pain score was reduced by 52% Most of the patients had normal menstrual periods No typical peri-menopausal symptoms were reported There were no significant changes in bone mineral density and sex hormone levels About 190 million women worldwide have endometriosis, making up a market size of $200billion SHANGHAI, Oct. 8, 2025 -- Hope Medicine Inc. ('HopeMed'), a clini
- 김갑성 기자
- 2025-10-08 09:08
New White Paper by APAC CVD Alliance and Deloitte Charts Path to Tackle Rising Heart Failure Burden in Asia-Pacific

32 million people in Asia-Pacific live with heart failure, and this number is rising fast. New blueprint targets a 20% cut in hospitalisations and 15% boost in survival rates within 5 years. Urgent call for early diagnosis, digital and community-based care, and sustainable financing to save lives and reduce costs. SINGAPORE, Oct. 8, 2025 -- The Asia Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), in collaboration with Deloitte, has released a groundbreaking White Paper, Improving Heart Failure Policy and Management in Asia Pacific: Opportunities for Impact
- 김갑성 기자
- 2025-10-08 09:00
CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology

SHANGHAI, Oct. 8, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of CT071 (an autologous CAR T-cell product targeting GPRC5D) for the treatment of relapsed/refractory multiple myeloma (R/R MM) in an investigator-initiated trial (NCT05838131) have been published in The Lancet Haematology. The article was titled "GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
- 김갑성 기자
- 2025-10-08 08:15
New Global Beauty & Wellbeing Report unveils Emotional Wellbeing as the True Face of Beauty

[ 메디채널 김갑성 기자 ] New proprietary research from Oriflame redefines beauty as a powerful driver of wellbeing STOCKHOLM, Oct. 8, 2025 -- Global beauty and wellbeing company, Oriflame, today releases its first Beauty & Wellbeing Report, revealing a major shift in how women around the world experience and define beauty. Based on a study of 3,500 women across seven countries, the report highlights the powerful role beauty plays in enhancing emotional wellbeing, self-confidence, and daily self-care. The findings reveal that beauty today is not about chasing perfection, but about f
- 김갑성 기자
- 2025-10-08 07:01
Global Direct Selling Leader QNET Celebrates 27 Years, Showcasing Economic Impact and Announces Landmark Ghana Convention

PENANG, Malaysia, Oct. 8, 2025 -- QNET, a leading global lifestyle and wellness direct selling company, concluded its spectacular 27th-anniversary convention, V-Malaysia 2025, in Penang this week. The event, endorsed by Tourism Malaysia, welcomed over 10,000 independent distributors from more than 30 countries, serving as a powerful testament to the company's global community and the significant economic benefits of its flagship events. Held for the 13th consecutive year in Penang, the five-day convention underscored Malaysia's position as a premier MICE (Meetings, Incentives,
- 김갑성 기자
- 2025-10-08 06:06
Cyteph Completes Recruitment for Phase I Clinical Trial of CYT-101 in Patients with Recurrent Glioblastoma Multiforme Brain Cancer

BRISBANE, Australia, Oct. 8, 2025 -- Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully completed recruitment for its first-in-human Phase I clinical trial of CYT-101. CYT-101 is a novel off-the-shelf, HLA-matched CMV-specific T cell therapy for the treatment of glioblastoma multiforme (GBM) and other solid cancers. GBM is an aggressive brain cancer and one of the deadliest solid cancers in adults, with limited treatment options available. The unique advantage of targeting CMV antigens
- 김갑성 기자
- 2025-10-08 06:00
밀리켄앤드컴퍼니, Millad ClearX™ 9000 출시: 폴리프로필렌용 차세대 투명화 기술

첨가제 사용량을 줄여 탁월한 투명도 구현 - 생산 공정 간소화 및 가공업·수지 생산업에 다양한 배합 옵션 제공 스파턴버그, 사우스캐롤라이나, 2025년 10월 8일 -- 밀리켄앤드컴퍼니(Milliken & Company)가 폴리프로필렌(PP)용 차세대 투명화 기술인 Millad ClearX™ 9000을 새롭게 출시했다고 발표했다. 이 제품은 첨가제 사용량을 줄이면서도 초고투명성을 구현하도록 설계됐다. Millad ClearX™ 9000은 식품 포장, 가정용 저장 용기, 의료용 제품 등 사용에 이상적이며, 투명한 PP 제품의 가치, 심미성, 공정 효율성 측면에서 새로운 기준을 제시한다. 입증된 Millad® 플랫폼을 기반으로 구축된 Millad ClearX™ 9000은 제조업체에 다음과 같은 고급 솔루션을 제공한다. 첨가제 사용 효율을 높여 초고투명 PP를 구현함으로써, 필요한 투명화 첨가제의 양을 감소시킨다. 추출 및 용출 비율을 낮춰, 식품 접촉용 및 의료용 PP 포장과 부품에서 안전성을 강화한다. 이전 세대 대비 가공 호환성을 개선해 운영 효율성 향
- 김갑성 기자
- 2025-10-08 01:33
An Era Where Meditation Becomes a Quantifiable Achievement -- Japan's First "Quantified Meditation Challenge"

TOKYO, Oct. 7, 2025 -- Meditation entered a new era as the World Meditation League (WML), and All Here introduced Japan's first Tokyo Quantified Meditation Challenge in the gardens of Happo-en. This unprecedented event took meditation beyond personal introspection — transforming it into a measurable, observable, and competitive discipline through neuroscience. For the first time, audiences witnessed meditation in real time, as brain activity, attention, self-awareness and inner silence were displayed as quantifiable data on screen. Technology × Archi
- 김갑성 기자
- 2025-10-07 21:24
Metabolon's Metabolomics Services Now Cited in More Than 4,000 Peer-Reviewed Publications

Metabolon's best-in-class metabolomics leadership accelerates as metabolomics becomes a standard inclusion in global multiomics studies MORRISVILLE, N.C., Oct. 7, 2025 -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced that its metabolomics services have now been cited in more than 4,000 peer-reviewed publications, far more than any other metabolomics provider in the life sciences industry. Publications refer
- 김갑성 기자
- 2025-10-07 21:00
ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization

Showcasing at AAO 2025: NEW 510k CLEARANCE SUPPORTS MORE INFORMED DECISION MAKING & PATHOLOGY DETECTION: Showcasing optical coherence tomography angiography (OCT-A) with ZEISS CIRRUS AngioPlex® with noninvasive imaging of the retinal and choroidal vasculature; now with 510k clearance and CE approval, ICGA for CLARUS® 700 offers FA + ICG simultaneous capture. OPTIMIZED RETINAL SURGICAL EXPERIENCE: Announcing updates to DORC instruments to expand surgeons' options, including new gauges added to the range of subretinal injection cannulae and a new Midfield endoillu
- 김갑성 기자
- 2025-10-07 21:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분